Connect with us


Five Oil Refiner Investments to Buy as ‘Golden Age’ Starts Amid War

Five oil refiner investments to buy provide a gusher of opportunities as the sector embarks upon what BofA Global Securities calls a new “golden age,”…



Five oil refiner investments to buy provide a gusher of opportunities as the sector embarks upon what BofA Global Securities calls a new “golden age,” despite Russia’s President Vladimir Putin’s invasion and continued devastation of Ukraine and its people.

The five oil refiner investments to buy feature three stocks and two broad commodity funds that offer a chance to benefit from multiple catalysts. U.S. oil refiners hold structural cost advantages compared to international peers and should benefit from an expected post-COVID recovery in demand and refinery closings that reduce supply and lift margins.

BofA Global Securities recently released a research report that declared a new regional ‘Golden Age’ for U.S. refining. The basis for that view is valuation aided by sustainable free cash flow (FCF) that measures the cash left after a company pays its operating expenses and capital expenditures.

Free cash flow yields are at their highest levels in a decade to help shift momentum toward oil refiners, BofA reported. Recent geopolitical events, such as Putin’s unrelenting attack of Ukraine, underscore the consequences of underinvestment in production, the investment firm wrote.

Click here for a free two-week trial of Stock Rover.

Five Oil Refiner Investments to Buy Aided by Economic Sanctions 

The shelling of hospitals, schools, residential areas, churches, nuclear power plants, oil refineries and a theater used as a shelter became a precursor to brutal rapes, torture and outright executions of Ukrainian civilians that caused many countries to put economic sanctions on Russia. Among those sanctions is severing ties with Russia as a provider of oil or natural gas, or significantly slashing such trade.

Russia’s losses due directly to Putin’s policies are leading to potential gains for Western oil refiners that are trying to fill the void for European customers seeking to wean themselves away buying energy from Russia that Putin is using to fund his invasion of Ukraine. As the old adage goes, there always is a bull market somewhere and one of the latest is in the oil patch.

One of the biggest large-cap energy companies in the market is Exxon Mobil Corp. (NYSE: XOM), a recent addition to the recommendations in the Fast Money Alert trading service led by seasoned stock pickers Mark Skousen, PhD, and Jim Woods. The integrated oil and gas company explores for, produces and refines oil around the world.

Mark Skousen, a descendant of Benjamin Franklin, talks to Paul Dykewicz. Skousen leads the Forecasts & Strategies newsletter, along with the Five Star Trader, Home Run Trader, TNT Trader and Fast Money Alert services.

Exxon Mobil Leads the Five Oil Refiner Investments to Buy

Irving, Texas-based Exxon Mobil produced an average of 2.3 million barrels of liquids and 8.5 billion cubic feet of natural gas per day in 2021. At the end of 2021, its reserves totaled 18.5 billion barrels of oil equivalent, including 66% from liquids. The company is the world’s largest refiner with a total global refining capacity of 4.6 million barrels of oil per day to rank as one of the world’s largest manufacturers of commodity and specialty chemicals.

“Size does matter when you are talking about oil and gas companies,” Skousen and Woods wrote to their Fast Money Alert subscribers. “What also matters is that oil prices have soared due to a combination of robust demand dynamics and constricted supply caused in part by Russia waging war against Ukraine.”

Paul Dykewicz meets with Jim Woods, who leads the Successful Investing and Intelligence Report investment newsletters, as well as the Bullseye Stock Trader, High Velocity Options and Fast Money Alert trading services.

With no end for Putin’s war in sight, the “smart money” is betting on higher energy prices, and the even smarter money is buying XOM, Skousen and Woods wrote. The proof comes from a 7.17% rise in the last week, a 45.56% jump so far this year and a 55.88% surge in the past 12 months.

Chart courtesy of

Another investment professional who recommends Exxon Mobil is Bryan Perry, head of the Cash Machine investment newsletter, as well as the Premium Income, Quick Income Trader, Hi-Tech Trader and Breakout Options Alert advisory services. Perry, who has a track record for profitably recommending dividend-paying oil and natural gas companies, also is known for finding high-income investments.

Bryan Perry heads the Cash Machine newsletter.

Exxon Mobil offers a current dividend yield of 4%. BofA has placed a $120 price target on the stock.

Money Manager Picks One of Five Oil Refiner Investments to Buy

A third investment professional who is recommending Exxon Mobil is Michelle Connell, a former portfolio manager who now serves as president of Dallas-based Portia Capital Management. Connell also told me she likes Valero Energy Corp. (NYSE: VLO), of San Antonio, Texas, offering a current dividend yield of 3.4%.

Valero is San Antonio’s largest publicly traded company and among the world’s largest independent petroleum refiners. It also claims to be North America’s largest producer of renewable fuels, as well as the world’s second-largest producer of sustainable diesel.

Michelle Connell, CEO, Portia Capital Management

Connell said her reasons for recommending Valero include:

  • Its status as the second-largest refiner in the United States.
  • U.S. refiners wield cost advantages compared to foreign competitors in the European Union and elsewhere.
  • The company’s natural gas for refining oil is the cheapest in the United States.
  • Analysts recently boosted VLO earnings estimates and price targets.
  • Its potential 12-month upside: 15-20%. BofA set a $140 price target.
  • A dividend yield of 3.4%.

“The fundamentals that drove strong results in the first quarter, particularly in March, continue to provide a positive backdrop for refining margins,” said Valero’s Chairman and Chief Executive Officer Joe Gorder, when the company reported its latest financial results.

Chart courtesy of

BofA Recommends Two of the Five Oil Refiner Investments to Buy

BofA also recommends VLO but cautions downside risks to its price objective include the company’s heavy weighting toward “sour crude.” As light-heavy crude differentials narrow, the benefits of a more complex refinery may dim and delay return on investment, BofA continued.

Plus, the company is vulnerable to a dip in refining margin, BofA opined. If demand for refined products is weaker than expected, or if oil prices remain robust, margins could be pressured.

Other risks include potential increases in operating expenditures, capital expenditures and taxes. Another risk remains due to the uncertainty of whether tax reform will be passed.

Potential outperformance of the price target for VLO could come from higher-than-expected spreads and stronger-than-forecast gasoline demand, according to BofA.

PBF Energy Earns Spot Among Five Oil Refiner Investments to Buy

PBF Energy Inc., (NYSE: PBF), of Parsippany-Troy Hills, New Jersey, is one of the largest independent petroleum refiners and suppliers of unbranded transportation fuels, heating oil and petrochemicals. 

BofA gave PBF a $35 price objective, based on an assessed discounted cash flow (DCF) value that treats the assets as annuities after deducting maintenance capital. The investment firm used a long-term Gulf Coast 321 crack spread in its benchmark assumptions of $11.50/bbl., a long-term crude differential of $3.5, a weighted average cost of capital (WACC) of 9.3%, a zero terminal growth rate and a 22% corporate tax rate.

Potential for PBF to outperform PBF’s price objective could include crude spreads and crack spreads remaining above BofA’s expectations, higher-than-expected earnings and improved valuation. Downside risks to meeting BofA’s price objective could occur if margins and crude spreads compress faster than forecast, hurting earnings and share price.

Chart courtesy of

Pension Fund Chief Picks Two of Five Oil Refiner Investments to Buy

Beware of overbought oil stocks due to the surge in their prices so far this year,” said Bob Carlson, chairman of the Board of Trustees of Virginia’s Fairfax County Employees’ Retirement System with more than $4 billion in assets. Investors are worried that monetary tightening by the Federal Reserve and slower growth in China due to surging COVID-19 cases will reduce global growth and therefore weaken demand for energy.

“My top pick remains the ETF Energy Select Sector SPDR (XLE),” said Carlson, who also leads the Retirement Watch investment newsletter. “It tracks the S&P 500 energy sector, which is the top-performing sector in the S&P 500 in 2022 after years of underperforming the rest of the index.”

The ETF holds 21 stocks and three other types of investments. About 76% of the fund is in its 10 largest positions. Exxon Mobil (NYSE: XOM) was almost 23% of the fund, and Chevron (NYSE: CHX) was just over 21% of the fund. Other major holdings include EOG Resources (NYSE: EOG), Schlumberger NV (NYSE: SLB) and Conoco Phillips (NYSE: COP).

The diversified energy fund holds a portfolio of refiners, exploration and production (E&P) stocks, as well as companies engaged in two or more activities. XLE is up 61.60% in the last 12 months, 38.83% for the year to date, 12.50% in the past three months and 3.62% in last week. The gain in the past week shows the fund remains on the rise.

“As long as economic growth remains solid, demand will exceed supply and support high prices for energy products,” Carlson said.

Even though companies are working to increase production, it takes a “long time” to do so with new sources or to restore old ones that have been shut down, Carlson said.

Chart courtesy of

MLOAX Joins Five Oil Retailer Investments to Buy 

A fairly aggressive fund is Cohen & Steers MLP & Energy Opportunity (MLOAX), Carlson said. It looks for companies in exploration, production, gathering, transportation, processing, storage, refining, distribution, or marketing of oil, natural gas and other energy sources.

The fund’s largest holding is Enbridge Inc. (NYSE: ENB), which has an extensive pipeline network that transports natural gas and other energy products. The fund’s second-largest holding is Cheniere Energy Inc. (NYSEAMERICAN: LNG), which exports liquefied natural gas (LNG). Other top holdings are the Williams Companies (NYSE: WMB), TC Energy (NYSE: TRP) and Energy Transfer LP (NYSE: ET).

The fund has 56 positions, with 55% of the fund in the 10 largest positions. MLOAX is up 33.64% in the past 12 months and 20.73% for the year to date. It also has climbed 11.75% for the past three months and 2.41% in the last week.

As an open-ended mutual fund with several share classes, investors should determine which share class has the lowest cost by inquiring with their brokers.

Chart courtesy of

COVID-19 Infects More than Half the People in America

COVID-19 cases and hospitalizations have risen about 10% in the last week. The U.S. Centers for Disease Control and Prevention (CDC) also has reported more than half the people in America, including most children, have been infected with the coronavirus.

In China, lockdowns have affected at least 373 million people, including roughly 40% of the country’s gross domestic product (GDP). A key effect is continued disruption of the world’s supply chain for many products, including oil.

Most of Shanghai’s 25 million residents remain in lockdown, as the Chinese military and additional health workers have been sent there to aid in the response. Shanghai, home to the world’s largest port, has strained to unload cargo due to strict regulations that have caused shipping containers to stack up. Some frustrated Shanghai residents have taken videos that went viral to show people screaming from high-rise buildings about needing food, but the government is trying to crack down on the posting of such expressions of frustration.

Also in China, young children with COVID-19 have been separated forcibly from their parents, fueling public discord, as Chinese leaders seek to stop the spread of a new, contagious subvariant of Omicron, BA.2. The variant also is causing a new wave of infections in European nations that include Germany, the Netherlands and Switzerland.

U.S. COVID Booster Shots Top 1 Million and Deaths Near 1 Million 

COVID-19 deaths worldwide exceeded 6.24 million to total 6,240,888 on May 3, according to Johns Hopkins University. Cases across the globe have jumped to 514,913,818.

U.S. COVID-19 cases, as of May 3, hit 81,506,075, with deaths rising to 994,744. America has the dubious distinction as the nation with the most COVID-19 cases and deaths.

Also as of May 3, 257,823,699 people, or 77.7% of the U.S. population, have obtained at least one dose of a COVID-19 vaccine, the CDC reported. Fully vaccinated people total 219,849,502 or 66.2% of the U.S. population, according to the CDC. America also has topped a key milestone by giving a COVID-19 booster vaccine to 100.8 million people.

The five oil refiner investments to buy offer another niche of energy stocks and funds that show signs of further gains ahead. Investors willing to buy after the assets have risen significantly in value could be rewarded by additional gains ahead, even if the easy money has gone to others.

Paul Dykewicz,, is an accomplished, award-winning journalist who has written for Dow Jones, the Wall Street Journal, Investor’s Business Daily, USA Today, the Journal of Commerce, Seeking Alpha, Guru Focus and other publications and websites. Paul, who can be followed on Twitter @PaulDykewicz, is the editor of and, a writer for both websites and a columnist. He further is editorial director of Eagle Financial Publications in Washington, D.C., where he edits monthly investment newsletters, time-sensitive trading alerts, free e-letters and other investment reports. Paul previously served as business editor of Baltimore’s Daily Record newspaper. Paul also is the author of an inspirational book, “Holy Smokes! Golden Guidance from Notre Dame’s Championship Chaplain,” with a foreword by former national championship-winning football coach Lou Holtz. The book is great as a gift and is endorsed by Joe Montana, Joe Theismann, Ara Parseghian, “Rocket” Ismail, Reggie Brooks, Dick Vitale and many others. Call 202-677-4457 for multiple-book pricing.

The post Five Oil Refiner Investments to Buy as ‘Golden Age’ Starts Amid War appeared first on Stock Investor.

Read More

Continue Reading


Family Of College Student Who Died From COVID-19 Vaccine Sues Biden Administration

Family Of College Student Who Died From COVID-19 Vaccine Sues Biden Administration

Authored by Zachary Stieber via The Epoch Times (emphasis…



Family Of College Student Who Died From COVID-19 Vaccine Sues Biden Administration

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

The family of a college student who died from heart inflammation caused by Pfizer’s COVID-19 vaccine has sued President Joe Biden’s administration, alleging officials engaged in “willful misconduct.”

George Watts Jr. in a file image. (Courtesy of the Watts family)

U.S. Department of Defense (DOD) officials wrongly promoted COVID-19 vaccination by repeatedly claiming the available vaccines were “safe and effective,” relatives of George Watts Jr., the college student, said in the new lawsuit.

That promotion “duped millions of Americans, including Mr. Watts, into being DOD’s human subjects in its medical experiment, the largest in modern history,” the suit states.

The Public Readiness and Emergency Preparedness Act allows lawsuits against certain people if they have engaged in “willful misconduct” and if that misconduct caused death or serious injury.

COVID-19 vaccines are covered by the act due to a declaration entered during the Trump administration in 2020 after COVID-19 began circulating.

DOD’s conduct and the harm caused as alleged within the four corners of the lawsuit speaks for itself,” Ray Flores, a lawyer representing the Watts family, told The Epoch Times via email. “I have no further comment other than to say: My only duty is to advocate for my client. If the DOD conveys a settlement offer, I will see that it’s considered.”

The suit was filed in U.S. court in Washington.

The Pentagon and the Department of Justice did not respond to requests for comment.

Watts Suddenly Died

Watts was a student at Corning Community College when the school mandated COVID-19 vaccination for in-person classes in 2021. He received one Pfizer dose on Aug. 27, 2021, and a second dose approximately three weeks later.

Watts soon began experiencing a range of symptoms, including tingling in the feet, pain in the heels, numbness in the hands and fingers, blood in his sperm and urine, and sinus pressure, according to family members and health records.

Watts went to the Robert Packer Hospital emergency room on Oct. 12, 2021, due to the symptoms. X-rays showed clear lungs and a normal heart outline.

Watts was sent home with suggestions to follow up with specialists but returned to the emergency room on Oct. 19, 2021, with worsening symptoms despite a week of the antibiotic Augmentin. He was diagnosed with sinusitis and bronchitis.

While speaking to his mother at home on Oct. 27, 2021, Watts suddenly collapsed. Emergency medical personnel rushed to the home but found him unresponsive. He was rushed to the same hospital in an ambulance. He was pronounced deceased at age 24.

According to a doctor at the hospital, citing hospital records and family members, Watts had no past medical history on file that would explain his sudden death, with no known history of substance abuse or obvious signs of substance abuse. His mother described her son as a “healthy young male.”

Dr. Robert Stoppacher, a pathologist who performed an autopsy on the body, said that the death was due to “COVID-19 vaccine-related myocarditis.” The death certificate listed no other causes. A COVID-19 test returned negative. Dr. Sanjay Verma, based in California, reviewed the documents in the Watts case and said that he believed the death was caused by the COVID-19 vaccination.

Pfizer did not respond to a request for comment.

Watts Took Vaccine Under Pressure

The community college mandate included a 35-day grace period following approval by the U.S. Food and Drug Administration (FDA) of a COVID-19 vaccine.

The Moderna, Pfizer, and Johnson & Johnson vaccines were given emergency use authorization early in the pandemic. The FDA approved the Pfizer shot on Aug. 23, 2021. It was the first COVID-19 vaccine approval. But doses of the approved version of the shot, branded Comirnaty, were not available for months after the approval.

Read more here...

Tyler Durden Fri, 06/02/2023 - 23:00

Read More

Continue Reading


US Sent Billions in Funding to China, Russia For Cat Experiments, Wuhan Lab Research: Ernst

US Sent Billions in Funding to China, Russia For Cat Experiments, Wuhan Lab Research: Ernst

Authored by Mark Tapscott via The Epoch Times…



US Sent Billions in Funding to China, Russia For Cat Experiments, Wuhan Lab Research: Ernst

Authored by Mark Tapscott via The Epoch Times (emphasis ours),

Hundreds of millions of U.S. tax dollars went to recipients in China and Russia in recent years without being properly tracked by the federal government, including a grant that enabled a state-run Russian lab to test cats on treadmills, according to Sen. Joni Ernst (R-Iowa).

Sen. Joni Ernst (R-Iowa) speaks at a Senate Republican news conference in the U.S. Capitol on March 9, 2022. (Anna Moneymaker/Getty Images)

Ernst and her staff investigators, working with auditors at the Government Accountability Office (GAO) and the Congressional Research Service, as well as two nonprofit Washington watchdogs—Open The Books (OTB) and the White Coat Waste Project (WCWP)—discovered dozens of other grants that weren’t counted on the federal government’s internet database.

While the total value of the uncounted grants found by the Ernst team is $1.3 billion, that amount is just the tip of the iceberg, the GAO reported.

Among the newly discovered grants is $4.2 million to China’s infamous Wuhan Institute of Virology (WIV) “to conduct dangerous experiments on bat coronaviruses and transgenic mice,” according to a May 31 Ernst statement provided to The Epoch Times.

The $4.2 million exposed by Ernst is in addition to previously reported funding to the WIV for extensive gain-of-function research by Chinese scientists, much of it funded in whole or part prior to the COVID-19 pandemic by National Institutes for Health (NIH) grants channeled through the EcoHealth Alliance medical research nonprofit.

The NIH has awarded seven grants totaling more than $4.1 million to EcoHealth to study various aspects of SARS, MERS, and other coronavirus diseases.

Buying Chinese Puppy Parts

As part of another U.S.-funded grant, hearts and other organs from 425 dogs in China were purchased for medical research.

These countryside dogs in China are part of the farmer’s household; they were mainly used for guarding. Their diet includes boiled rice, discarded raw food animal tissues, and whatever dogs can forage. These dogs were sold for food,” an NIH study uncovered by the Ernst researchers reads.

Other previously unreported grants exposed by the Ernst team include $1.6 million to Chinese companies from the federal government’s National School Lunch Program and $4.7 million for health insurance from a Russian company that was sanctioned by the United States in 2022 as a result of the invasion of Ukraine.

“It’s gravely concerning that Washington’s reckless spending has reached the point where nobody really knows where all tax dollars are going,” Ernst separately told The Epoch Times. “But I have the receipts, and I’m shining a light on this, so bureaucrats can no longer cover up their tracks, and taxpayers can know exactly what their hard-earned dollars are funding.”

The problem is that federal officials don’t rigorously track sub-awards made by initial grant recipients, according to the Iowa Republican. Such sub-awards are covered by a multitude of federal regulations that stipulate many conditions to ensure that the tax dollars are appropriately spent.

The GAO said in an April report that “limitations in sub-award data is a government-wide issue and not unique to U.S. funding to entities in China.”

GAO is currently examining the state of federal government-wide sub-award data as part of a separate review,” the report reads.

Peter Daszak, right, the president of the EcoHealth Alliance, is seen in Wuhan, China, on Feb. 3, 2021. (Hector Retamal/AFP via Getty Images)

The Eco-Health sub-awards to WIV illustrate the problem.

“Despite being required by law to make these receipts available to the public on the website, EcoHealth tried to cover its tracks by intentionally not disclosing the amounts of taxpayer money being paid to WIV, which went unnoticed for years,” Ernst said in the statement.

“I was able to determine that more than $490 million of taxpayer money was paid to organizations in China [in] the last five years. That’s ten times more than GAO’s estimate! Over $870 million was paid to entities in Russia during the same period!

Together that adds up to more than $1.3 billion paid to our adversaries. But again, these numbers still do not represent the total dollar amounts paid to institutions in China or Russia since those numbers are not tracked and the information that is being collected is incomplete.”

Adam Andrzejewski, founder and chairman of OTB, told The Epoch Times, “When following the money at the state and local level, the real corruption exists in the subcontractor payments. At the federal level, the existing system doesn’t even track many of those recipients.

“Without better reporting, agencies and appropriators don’t truly understand how tax dollars were used. We now know that taxpayer dollars are traded further downstream than originally realized with third- and fourth-tier recipients. These transactions need scrutiny. Requiring recipients to account for where and how they actually spend each dollar creates a record far better than agencies are capable of generating.”

Read more here...

Tyler Durden Fri, 06/02/2023 - 19:40

Read More

Continue Reading


OraSure Technologies’ CFO Makes Bold Insider Purchase, Reigniting Investor Confidence

Executive Kenneth McGrath’s $500,000 buy read as promising signal about future for diagnostic test developer OraSure Technologies (NASDAQ:OSUR) saw…




Executive Kenneth McGrath’s $500,000 buy read as promising signal about future for diagnostic test developer

OraSure Technologies (NASDAQ:OSUR) saw a stock price re-rate on Thursday, climbing 11% after investors became aware of its CFO Kenneth McGrath buying shares in the diagnostic test developer.  This latest rally in OSUR stock, gives traders and investors hope that the strong momentum from the beginning of 2023 might return.

OSUR shares had mounted an impressive 54% rally for 2023 through to May 10, when the first-quarter results update spooked investors. 

The CFO’s trade was initially spotted on Fintel’s Insider Trading Tracker following the filing with the Securities and Exchange Commission.

Big Holdings Boost

In the Form 4 filing, McGrath, who assumed CFO duties in August 2022, disclosed buying 100,000 shares on May 30 in the approved trading window that was open post results.

McGrath on average paid $4.93 per share, giving the total transaction a value just shy of $500,000 and boosted his total share count ownership to 285,512 shares.

The chart below from the insider trading and analysis report for OSUR shows the share price performance and profit made from company officers in previous transactions:

OraSure Technologies

Prior to joining OraSure, McGrath had an impressive eight-year tenure at Quest Diagnostics (NYSE:DGX), where he rose to the position of VP of Finance before departing. This is the first time that the CFO has bought stock in the company since August 2022. It is also worth noting that the purchase followed strong Q1 financial results, which exceeded Street forecasts.

Revenue Doubles

In its recently published Q1 update, OraSure Technologies told investors that it generated a whopping 129% increase in revenue to $155 million, surpassing analyst expectations of around $123 million. 

Notably, the revenue growth was driven primarily by the success of OraSure’s COVID-19 products, which accounted for $118.4 million in revenue for the quarter and grew 282% over the previous year.

The surge in revenue for this product was largely driven by the federal government’s school testing program, which led to record test volumes. However, it is important to note that demand for InteliSwab is expected to decline in Q2 2023, prompting OraSure to scale down its COVID-19 production operations. As part of its broader strategy to consolidate manufacturing, the company plans to close an overseas production facility.

While the COVID-19 products division has been instrumental in OraSure’s recent success, its core business delivered stable flat sales of $36.6 million during the quarter. 

In terms of net income, OraSure achieved an impressive result of $27.2 million, or $0.37 per share, in Q1, marking a significant improvement compared to the loss of $19.9 million, or a loss of $0.28 per share, in the same period last year. This result exceeded consensus forecasts of $0.16 per share. As of the end of the quarter, the company held $112.4 million in cash and cash equivalents.

Looking ahead to Q2, OraSure has provided revenue guidance in the range of $62 to $67 million, reflecting the lower order activity from the US government with $25 to $30 million expected sales for InteliSwab. The declining Covid related sales have been a core driver of the share price weakness in recent weeks.

While sales are likely to fall in the coming quarters, one positive for the company is its low debt balance during this period of rising cash rates. The chart below from Fintels financial metrics and ratios page for OSUR shows the cash flow performance of the business over the last five years.

OraSure Technologies

Analyst Opinions

Stephen’s analyst Jacob Johnson thinks that outside of Covid, OSUR continues to execute on several cost and partnership initiatives which he believes appears to be bearing fruit. Johnson pointed out that three partnerships were signed during the quarter.

The analyst thinks that the ex-Covid growth story will be the new focus for investors from now on. The brokerage maintained its ‘equal-weight’ recommendation and $6.50 target price on the stock, matching Fintel’s consensus target price, suggesting OSUR stock could rise a further 29% in the next 12 months. 

The post OraSure Technologies’ CFO Makes Bold Insider Purchase, Reigniting Investor Confidence appeared first on Fintel.

Read More

Continue Reading